$1.39
-0.01-0.71%
Last update: Dec 15, 2:39 PM
Tools
Free Benzinga Pro Trial
Calendars
Trade Ideas
Short Interest
Compare Best Stocks
Comments
Loading...
Macrogenics Insider Trading Activity | NASDAQ:MGNX | Benzinga
Track the latest Macrogenics insider trading activity. Stay informed on recent buys, sells, and market impact for Macrogenics stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Macrogenics Inc Insiders Doing?
Insiders have report no purchases/sales in the last 30 days.
Notable Recent Insider Buys and Sales
There has been no Insider buying or selling in the last 90 days.
Ownership Statistics for Macrogenics Inc
Shares Outstanding
63.259M
Insider Shares Owned
1.701M
Insider Percentage Owned
2.69%
Institutional Shares Held
20.689M
Institutional Percentage Held
32.7%
| Aug 21, 2025 | WILLIAM HEIDEN | DIRECTOR | 100.00K | $1.51 | $150.51K | BUY | 909.09% | 111.00K | Aug 19 - Aug 20 | View |
| Feb 19, 2025 | Beth Smith | VP, CONTROLLER & TREASURER | 672.00 | $2.56 | -$1.08K | SELL-OPTIONS | 7.58% | 9.53K | Feb 15 | View |
| Apr 08, 2024 | Stuart Jeffrey Peters | SENIOR VP AND GENERAL COUNSEL | -8.89K | $10.18 | -$594.30K | SELL | -100.00% | 0.00 | Apr 04 | View |
| Mar 08, 2024 | Stuart Jeffrey Peters | SENIOR VP AND GENERAL COUNSEL | 0.00 | $16.20 | -$208.06K | SELL-OPTIONS | 0.00% | 8.89K | Mar 06 | View |
| Mar 06, 2024 | Blasius Eric Risser | CHIEF OPERATING OFFICER | -26.16K | $14.96 | -$661.25K | SELL | -40.21% | 38.90K | Mar 04 | View |
| Mar 06, 2024 | Thomas Spitznagel | SR VP, TECHNICAL OPS | 0.00 | $15.75 | -$85.00K | SELL-OPTIONS | 0.00% | 8.32K | Mar 04 | View |
| Mar 06, 2024 | James Karrels | SVP, CFO AND SECRETARY | -30.00K | $20.50 | -$615.00K | SELL | -14.89% | 171.45K | Mar 04 | View |
| Feb 28, 2024 | Stuart Jeffrey Peters | SENIOR VP AND GENERAL COUNSEL | -16.12K | $17.22 | -$277.66K | SELL | -64.45% | 8.89K | Feb 26 | View |
| Feb 07, 2024 | Ezio Bonvini | SR VP, RESEARCH & CSO | -3.33K | $18.00 | -$60.01K | SELL | -4.47% | 71.33K | Feb 07 | View |
| Feb 07, 2024 | Stuart Jeffrey Peters | SENIOR VP AND GENERAL COUNSEL | 0.00 | $13.81 | -$410.79K | SELL-OPTIONS | 0.00% | 0.00 | Feb 05 | View |
| Feb 02, 2024 | Ezio Bonvini | SR VP, RESEARCH & CSO | -13.32K | $15.00 | -$199.74K | SELL | -15.13% | 74.67K | Feb 01 | View |
| Jan 22, 2024 | Ezio Bonvini | SR VP, RESEARCH & CSO | -13.32K | $12.00 | -$159.79K | SELL | -13.15% | 87.98K | Jan 19 | View |
| Dec 21, 2023 | Ezio Bonvini | SR VP, RESEARCH & CSO | -18.88K | $10.08 | -$190.31K | SELL | -15.71% | 101.30K | Dec 20 | View |
| Oct 04, 2023 | TARGET BIOTECH VBB BIOTECH AG | 10% OWNER | 150.00K | $4.46 | $669.59K | BUY | 1.53% | 9.93M | Oct 02 | View |
| Sep 11, 2023 | TARGET BIOTECH VBB BIOTECH AG | 10% OWNER | 200.00K | $5.26 | $1.05M | BUY | 2.09% | 9.78M | Sep 07 | View |
| Sep 01, 2023 | EDWARD HURWITZ | DIRECTOR | 15.00K | $4.91 | $73.65K | BUY | 82.99% | 33.07K | Aug 30 | View |
| Mar 14, 2023 | Stuart Jeffrey Peters | SENIOR VP AND GENERAL COUNSEL | -5.37K | $6.03 | -$32.39K | SELL | -100.00% | 0.00 | Mar 10 | View |
| Feb 16, 2023 | TARGET BIOTECH VBB BIOTECH AG | 10% OWNER | 500.00K | $5.07 | $2.53M | BUY | 5.51% | 9.58M | Feb 14 | View |
| Jan 23, 2023 | TARGET BIOTECH VBB BIOTECH AG | 10% OWNER | 150.00K | $5.30 | $794.92K | BUY | 1.68% | 9.08M | Jan 19 | View |
| Dec 28, 2022 | TARGET BIOTECH VBB BIOTECH AG | 10% OWNER | 400.00K | $5.75 | $2.30M | BUY | 4.69% | 8.93M | Dec 23 - Dec 27 | View |
| Nov 25, 2022 | TARGET BIOTECH VBB BIOTECH AG | 10% OWNER | 300.00K | $5.96 | $1.79M | BUY | 3.65% | 8.53M | Nov 22 | View |
| Oct 25, 2022 | TARGET BIOTECH VBB BIOTECH AG | 10% OWNER | 500.00K | $4.50 | $2.25M | BUY | 6.47% | 8.23M | Oct 21 - Oct 24 | View |
| Oct 21, 2022 | TARGET BIOTECH VBB BIOTECH AG | 10% OWNER | 454.40K | $3.89 | $1.77M | BUY | 6.25% | 7.73M | Oct 19 - Oct 20 | View |
| Jun 17, 2022 | James Karrels | SVP, CFO AND SECRETARY | 40.00K | $2.47 | $98.80K | BUY | 26.35% | 191.78K | Jun 15 | View |
| Nov 23, 2021 | TARGET BIOTECH VBB BIOTECH AG | 10% OWNER | 200.00K | $18.50 | $3.70M | BUY | 2.83% | 7.28M | Nov 19 | View |
| Sep 30, 2021 | TARGET BIOTECH VBB BIOTECH AG | 10% OWNER | 200.00K | $20.56 | $4.11M | BUY | 2.91% | 7.08M | Sep 28 - Sep 29 | View |
| Sep 20, 2021 | TARGET BIOTECH VBB BIOTECH AG | 10% OWNER | 600.00K | $20.61 | $12.36M | BUY | 9.56% | 6.88M | Sep 16 - Sep 17 | View |
| Jul 20, 2021 | Thomas Spitznagel | SR VP, BPD & MANUFACTURING | 0.00 | $16.26 | -$87.50K | SELL-OPTIONS | 0.00% | 0.00 | Jul 16 | View |
| Jun 23, 2021 | TARGET BIOTECH VAG BIOTECH BB | 10% OWNER | 75.00K | $21.74 | $1.63M | BUY | 1.21% | 6.28M | Jun 21 | View |
| Jun 17, 2021 | TARGET BIOTECH VAG BIOTECH BB | 10% OWNER | 175.00K | $20.82 | $3.64M | BUY | 2.90% | 6.20M | Jun 15 - Jun 16 | View |
| Apr 19, 2021 | Thomas Spitznagel | SR VP, BPD & MANUFACTURING | 0.00 | $19.21 | -$117.00K | SELL-OPTIONS | 0.00% | 0.00 | Apr 15 | View |
| Mar 24, 2021 | James Karrels | SVP, CFO AND SECRETARY | -15.00K | $33.00 | -$495.00K | SELL | -9.47% | 143.46K | Mar 22 | View |
| Mar 24, 2021 | Ezio Bonvini | SR VP, RESEARCH & CSO | -3.92K | $32.00 | -$125.34K | SELL | -4.67% | 79.89K | Mar 22 | View |
| Mar 09, 2021 | Stuart Jeffrey Peters | GENERAL COUNSEL | 0.00 | $19.00 | -$326.24K | SELL-OPTIONS | 0.00% | 0.00 | Mar 08 | View |
| Dec 30, 2020 | Blasius Eric Risser | — | 0.00 | $12.81 | -$11.29K | OPTION EXERCISE | 0.00% | 44.47K | Dec 29 | View |
| Dec 01, 2020 | Blasius Eric Risser | — | 0.00 | $12.43 | -$10.92K | OPTION EXERCISE | 0.00% | 44.47K | Nov 30 | View |
| Oct 29, 2020 | Blasius Eric Risser | — | 0.00 | $11.10 | -$28.77K | OPTION EXERCISE | 0.00% | 44.47K | Oct 28 | View |
| Sep 29, 2020 | Blasius Eric Risser | — | 0.00 | $13.42 | -$11.91K | OPTION EXERCISE | 0.00% | 44.47K | Sep 28 | View |
| Sep 21, 2020 | Ezio Bonvini | — | -62.85K | $30.50 | -$1.92M | SELL | -42.86% | 83.81K | Sep 17 - Sep 18 | View |
| Sep 10, 2020 | Kenneth Galbraith | — | 0.00 | $22.25 | -$202.05K | OPTION EXERCISE | 0.00% | 0.00 | Sep 09 | View |
| Aug 27, 2020 | Blasius Eric Risser | — | 0.00 | $14.30 | -$12.79K | OPTION EXERCISE | 0.00% | 44.47K | Aug 26 | View |
| Aug 21, 2020 | Thomas Spitznagel | — | 0.00 | $17.19 | -$145.20K | OPTION EXERCISE | 0.00% | 0.00 | Aug 20 | View |
| Jul 28, 2020 | Blasius Eric Risser | — | 0.00 | $13.46 | -$107.82K | OPTION EXERCISE | 0.00% | 44.47K | Jul 27 | View |
| Jul 06, 2020 | Stuart Jeffrey Peters | — | -202.00 | $30.00 | -$6.06K | SELL | -100.00% | 0.00 | Jul 02 | View |
| Jul 06, 2020 | Blasius Eric Risser | — | 0.00 | $15.76 | -$88.32K | OPTION EXERCISE | 0.00% | 44.47K | Jul 02 | View |
| Jun 25, 2020 | Blasius Eric Risser | — | 0.00 | $14.71 | -$13.78K | OPTION EXERCISE | 0.00% | 44.47K | Jun 24 | View |
| May 27, 2020 | Blasius Eric Risser | — | 0.00 | $13.77 | -$12.82K | OPTION EXERCISE | 0.00% | 44.47K | May 26 | View |
| May 21, 2020 | Thomas Spitznagel | — | 0.00 | $16.41 | -$133.43K | OPTION EXERCISE | 0.00% | 0.00 | May 20 | View |
| May 07, 2020 | Blasius Eric Risser | — | 0.00 | $11.21 | -$156.46K | OPTION EXERCISE | 0.00% | 44.47K | May 06 | View |
| Feb 21, 2020 | Blasius Eric Risser | — | 0.00 | $5.89 | -$4.95K | OPTION EXERCISE | 0.00% | 32.47K | Feb 20 | View |
| Feb 06, 2020 | Blasius Eric Risser | — | 0.00 | $5.47 | -$5.92K | OPTION EXERCISE | 0.00% | 32.47K | Feb 04 - Feb 05 | View |
| May 22, 2019 | Blasius Eric Risser | SR VP & CHIEF BUSINESS OFFICER | 0.00 | $9.74 | -$70.40K | SELL-OPTIONS | 0.00% | 30.81K | May 20 - May 22 | View |
| Feb 08, 2019 | Matthew Fust | DIRECTOR | 0.00 | $24.76 | -$63.91K | SELL-OPTIONS | 0.00% | 500.00 | Feb 06 | View |
| Feb 08, 2019 | Stuart Jeffrey Peters | GENERAL COUNSEL | -68.00 | $30.00 | -$2.04K | SELL | -25.19% | 202.00 | Feb 06 | View |
| Feb 08, 2019 | Thomas Spitznagel | SR VP, BPD & MANUFACTURING | 0.00 | $18.75 | -$39.81K | SELL-OPTIONS | 0.00% | 0.00 | Feb 06 | View |
| Mar 14, 2018 | Blasius Eric Risser | SR VP & CHIEF BUSINESS OFFICER | 0.00 | $16.01 | -$30.14K | SELL-OPTIONS | 0.00% | 9.10K | Mar 12 | View |
| Mar 07, 2018 | James Karrels | SVP, CFO AND SECRETARY | -5.00K | $31.00 | -$155.00K | SELL | -4.17% | 114.85K | Mar 05 | View |
| Mar 06, 2018 | Blasius Eric Risser | SR VP & CHIEF BUSINESS OFFICER | 0.00 | $15.47 | -$116.24K | SELL-OPTIONS | 0.00% | 9.10K | Mar 02 | View |
| Mar 01, 2018 | Blasius Eric Risser | SR VP & CHIEF BUSINESS OFFICER | 0.00 | $12.97 | -$24.07K | SELL-OPTIONS | 0.00% | 9.10K | Feb 28 | View |
| Mar 01, 2018 | Lynn Cilinski | VP, CONTROLLER AND TREASURER | 0.00 | $13.07 | -$572.35K | SELL-OPTIONS | 0.00% | 1.92K | Feb 28 | View |
| Jan 25, 2018 | Blasius Eric Risser | SR VP & CHIEF BUSINESS OFFICER | 0.00 | $11.72 | -$64.68K | SELL-OPTIONS | 0.00% | 9.10K | Jan 24 | View |
| Jan 18, 2018 | Marc Jon Wigginton | SR VP, CLINICAL DEV. & CMO | 0.00 | $12.35 | -$76.50K | SELL-OPTIONS | 0.00% | 30.00K | Jan 16 - Jan 17 | View |
| Nov 21, 2017 | Marc Jon Wigginton | SR VP, CLINICAL DEV. & CMO | 0.00 | $12.35 | -$76.50K | SELL-OPTIONS | 0.00% | 30.00K | Nov 21 | View |
| Oct 26, 2017 | Marc Jon Wigginton | SR VP, CLINICAL DEV. & CMO | 0.00 | $12.35 | -$153.00K | SELL-OPTIONS | 0.00% | 30.00K | Oct 25 | View |
| Jun 06, 2017 | Marc Jon Wigginton | SR VP, CLINICAL DEV. & CMO | 0.00 | $12.35 | -$76.50K | SELL-OPTIONS | 0.00% | 30.00K | Jun 05 | View |
| Apr 20, 2017 | Marc Jon Wigginton | SR VP, CLINICAL DEV. & CMO | 0.00 | $12.35 | -$229.50K | SELL-OPTIONS | 0.00% | 30.00K | Apr 19 | View |
| Oct 05, 2016 | Marc Jon Wigginton | SR VP, CLINICAL DEV. & CMO | 0.00 | $17.02 | -$246.40K | SELL-OPTIONS | 0.00% | 0.00 | Oct 03 | View |
| Oct 05, 2016 | Lynn Cilinski | VP, CONTROLLER AND TREASURER | 0.00 | $15.11 | -$176.59K | SELL-OPTIONS | 0.00% | 1.92K | Oct 03 | View |
| Aug 03, 2016 | Marc Jon Wigginton | SR VP CLINICAL DEV & CMO | 0.00 | $17.74 | -$521.60K | SELL-OPTIONS | 0.00% | 0.00 | Aug 01 | View |
| Jul 06, 2016 | Marc Jon Wigginton | SR VP CLINICAL DEV & CMO | 0.00 | $15.96 | -$112.60K | SELL-OPTIONS | 0.00% | 0.00 | Jul 01 | View |
| Jul 06, 2016 | Lynn Cilinski | VP, CONTROLLER AND TREASURER | 0.00 | $14.08 | -$234.47K | SELL-OPTIONS | 0.00% | 1.92K | Jul 01 | View |
| May 27, 2016 | Lynn Cilinski | VP, CONTROLLER AND TREASURER | 0.00 | $12.97 | -$120.30K | SELL-OPTIONS | 0.00% | 1.92K | May 27 | View |
| Mar 04, 2016 | Paulo Costa | DIRECTOR | 10.00K | $17.20 | $172.00K | BUY | 20.23% | 59.44K | Mar 03 | View |
| Jan 06, 2016 | Marc Jon Wigginton | SR VP, CLINICAL | 0.00 | $17.17 | -$249.40K | SELL-OPTIONS | 0.00% | 0.00 | Jan 04 | View |
| Nov 24, 2015 | Lynn Cilinski | VP, CONTROLLER AND TREASURER | -1.92K | $17.97 | -$237.53K | SELL | -49.97% | 1.92K | Jul 01 - Nov 23 | View |
| Nov 17, 2015 | Ezio Bonvini | SENIOR VP, RESEARCH | -3.12K | $31.44 | -$98.00K | SELL | -4.24% | 70.32K | Nov 16 | View |
| Oct 19, 2015 | Ezio Bonvini | SENIOR VP, RESEARCH | -6.23K | $25.21 | -$157.13K | SELL | -7.82% | 73.43K | Oct 15 | View |
| Oct 02, 2015 | Marc Jon Wigginton | SR VP, CLINICAL | 0.00 | $12.90 | -$82.05K | SELL-OPTIONS | 0.00% | 0.00 | Oct 01 | View |
| Aug 03, 2015 | Marc Jon Wigginton | SR VP, CLINICAL | 0.00 | $20.93 | -$324.50K | SELL-OPTIONS | 0.00% | 0.00 | Aug 03 | View |
| Jul 13, 2015 | Ezio Bonvini | SENIOR VP, RESEARCH | 0.00 | $19.40 | -$89.71K | SELL-OPTIONS | 0.00% | 36.79K | Jul 10 | View |
| Jul 01, 2015 | Lynn Cilinski | VP, CONTROLLER AND TREASURER | -1.92K | $19.04 | -$252.42K | SELL | -33.32% | 3.84K | Jul 01 | View |
| Jul 01, 2015 | Marc Jon Wigginton | SR VP, CLINICAL | 0.00 | $20.93 | -$162.25K | SELL-OPTIONS | 0.00% | 0.00 | Jul 01 | View |
| Jul 01, 2015 | Ezio Bonvini | SENIOR VP, RESEARCH | 0.00 | $19.39 | -$242.73K | SELL-OPTIONS | 0.00% | 36.79K | Jun 30 | View |
| Jun 25, 2015 | Ezio Bonvini | SENIOR VP, RESEARCH | -6.10K | $38.08 | -$232.17K | SELL | -25.69% | 17.64K | Jun 24 | View |
| Jun 24, 2015 | Ezio Bonvini | SENIOR VP, RESEARCH | -13.05K | $38.14 | -$497.88K | SELL | -35.48% | 23.74K | Jun 23 | View |
| Jun 16, 2015 | Lynn Cilinski | VP, CONTROLLER AND TREASURER | -5.70K | $17.97 | -$369.80K | SELL | -49.72% | 5.76K | Jun 15 | View |
| Jun 16, 2015 | Ezio Bonvini | SENIOR VP, RESEARCH | 0.00 | $17.36 | -$207.56K | SELL-OPTIONS | 0.00% | 36.79K | Jun 15 | View |
| May 18, 2015 | Ezio Bonvini | SENIOR VP, RESEARCH | 0.00 | $15.47 | -$184.06K | SELL-OPTIONS | 0.00% | 36.79K | May 15 | View |
| Apr 16, 2015 | Ezio Bonvini | SENIOR VP, RESEARCH | 0.00 | $17.34 | -$207.37K | SELL-OPTIONS | 0.00% | 36.79K | Apr 15 | View |
| Apr 03, 2015 | Marc Jon Wigginton | SR VP, CLINICAL | 0.00 | $17.78 | -$130.80K | SELL-OPTIONS | 0.00% | 0.00 | Apr 01 | View |
| Feb 03, 2015 | Marc Jon Wigginton | SR VP, CLINICAL | 0.00 | $17.87 | -$131.70K | SELL-OPTIONS | 0.00% | 0.00 | Feb 02 | View |
| Dec 23, 2014 | Kathryn Stein | SVP, PRODUCT DEV. & REGULATORY | 0.00 | $18.54 | -$404.22K | SELL-OPTIONS | 0.00% | 43.20K | Dec 22 | View |
| Dec 22, 2014 | Blasius Eric Risser | VP, BUSINESS DEVELOPMENT | 0.00 | $17.22 | -$325.60K | SELL-OPTIONS | 0.00% | 0.00 | Dec 18 | View |
| Dec 22, 2014 | Kathryn Stein | SVP, PRODUCT DEV. & REGULATORY | 0.00 | $16.86 | -$353.45K | SELL-OPTIONS | 0.00% | 43.20K | Dec 18 | View |
| Nov 25, 2014 | Eric Risser | VP, BUSINESS DEVELOPMENT | 0.00 | $14.35 | -$268.10K | SELL-OPTIONS | 0.00% | 0.00 | Nov 24 | View |
| Nov 24, 2014 | Kathryn Stein | SENIOR VP, PRD DEV & REG AFF | 0.00 | $13.86 | -$287.77K | SELL-OPTIONS | 0.00% | 43.20K | Nov 21 | View |
| Nov 17, 2014 | Kathryn Stein | SENIOR VP, PRD DEV & REG AFF | 0.00 | $12.12 | -$565.70K | SELL-OPTIONS | 0.00% | 43.20K | Nov 14 - Nov 17 | View |
| Nov 13, 2014 | Blasius Eric Risser | VP, BUSINESS DEVELOPMENT | -5.00K | $12.37 | -$576.20K | SELL | -100.00% | 0.00 | Nov 12 - Nov 13 | View |
| Oct 02, 2014 | Marc Jon Wigginton | SR V.P., CLINICAL | 0.00 | $12.59 | -$78.90K | SELL-OPTIONS | 0.00% | 0.00 | Oct 01 | View |
| Sep 02, 2014 | Blasius Eric Risser | VP, BUSINESS DEVELOPMENT | -8.32K | $20.89 | -$173.72K | SELL | -62.45% | 5.00K | Sep 02 | View |
| Aug 19, 2014 | Marc Jon Wigginton | SENIOR VP, CLINICAL DEV. | 0.00 | $12.61 | -$79.10K | SELL-OPTIONS | 0.00% | 0.00 | Aug 18 | View |
| Jul 01, 2014 | Blasius Eric Risser | VP, BUSINESS DEVELOPMENT | 0.00 | $11.39 | -$167.20K | SELL-OPTIONS | 0.00% | 13.32K | Jun 30 | View |
| May 30, 2014 | Kathryn Stein | SENIOR VP, PRD DEV & REG AFF | 0.00 | $10.23 | -$208.41K | SELL-OPTIONS | 0.00% | 43.20K | May 29 | View |
| Feb 18, 2014 | EDWARD HURWITZ | DIRECTOR | -308.51K | $36.50 | -$11.26M | SELL | -15.32% | 1.70M | Feb 18 | View |
| Feb 18, 2014 | ARNOLD ORONSKY | DIRECTOR | -200.00K | $36.50 | -$7.30M | SELL | -10.48% | 1.71M | Feb 18 | View |
| Oct 18, 2013 | Kenneth Galbraith | DIRECTOR | 1.32M | $16.00 | $750.00K | BUY | ∞ | 1.32M | Oct 16 | View |
FAQ
Q
Is insider trading legal?
A
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
Q
What are some examples of market manipulation?
A
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.
MGNX Insider Trading News
People Also Watch
Market Resources
Trading Tools & Education
- Benzinga Pro Trading Platform
- Options Trading Strategies and News
- Stock Market Trading Ideas and Analysis
- Technical Analysis Charts and Indicators
- Fundamental Analysis and Valuation
- Day Trading Guides and Strategies
- Live Investors Events
- Pre market Stock Analysis and News
- Cryptocurrency Market Analysis and News
Ring the Bell
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
© 2025 Benzinga | All Rights Reserved